Predictive biomarkers in metastatic kidney cancer

A review published in European Urology Focus looks at tools to optimise the choice and sequence of treatments to ensure the best clinical benefit for their metastatic renal cell carcinoma (RCC) patients. The review concludes that the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model is currently the only validated tool that can help clinicians decide which patients should receive sunitinib versus a combination of nivolumab and ipilimumab as a first treatment for metastatic RCC. Other tools are being actively investigated in clinical trials.

Read more in European Urology Focus here

Share this Post!


Related post

  TOP